Add Company
Join Now

IN8bio Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Employee Data

  • IN8bio has 28 Employees.(i)
  • IN8bio grew their employee count by -26% last year.

IN8bio's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M30%N/AN/A
#2
N/A2043%N/AN/A
#3
$6.7M33-6%N/AN/A
#4
$34.4M222-1%N/AN/A
#5
$5.2M670%$10MN/A
#6
$2M130%N/AN/A
#7
$7.5M370%$51.6MN/A
#8
$0.3M1-50%N/AN/A
#9
$4.3M21-16%$3.3MN/A
#10
$3.6M205%N/AN/A
Add Company

What Is IN8bio?

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic.\n\nFor more information about the Company and its programs, visit www.IN8bio.com.

keywords:N/A

N/A

Total Funding

28

Number of Employees

N/A

Revenue (est)

-26%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M28-3%N/A
#2
$4M28-28%N/A
#3
$2.5M2827%N/A
#4
$2M2833%$14.1M
#5
$7.8M288%N/A